[蒿草花粉症的发病特征及早期介入治疗的疗效]

[Onset feature and efficacy of early interventional treatment of Artemisia pollinosis].

作者信息

Ouyang Yuhui, Fan Erzhong, Li Ying, Zhang Luo

机构信息

Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Key Laboratory of Nasal diseases, Beijing Institute of Otorhinolaryngology, Beijing 100730, China.

出版信息

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Apr;49(4):272-6.

PMID:24931013

Abstract

OBJECTIVE

To analyze the clinical feature and treatment methods of Artemisia pollinosis.

METHODS

Skin prick test results of 14 426 cases from Beijing Tongren hospital and pollen concentration of Beijing observatory from 2007 to 2011 were analyzed to identify the clinical feature of Artemisia pollinosis patients and its correlation with the pollen concentration. Patients were given leukotriene receptor antagonists (Montelukast) for 2 weeks, followed by 4 weeks of mometasone furoate nasal spray (EIT group: n = 21), or only 4 weeks of mometasone furoate nasal spray (POT group: n = 16). The nasal symptom score was compared between 2 groups.SPSS 16.0 software was used to analyze the data.

RESULTS

Artemisia pollinosis accounted for 30.8% (4 442/14 426) of all SPT positive allergic rhinitis patients, and most Artemisia SPT positive results were strong positive(3 793/4 442, 85.4%); onset age peak of Artemisia pollinosis patients was at the age of 19 to 30, onset time concentrated in August to September, was consistent with the peak period of Artemisia pollen concentration; EIT treatment using leukotriene receptor antagonists two weeks before pollen season significantly improved sneeze, sniveling and rhinocnesmus symptoms (t value was 3.28, 3.92, 3.09, respectively, all P < 0.01) compared with post-onset treatment (POT). But nasal obstruction and cough symptoms had no significant difference between two groups (t value was 0.85, 1.52, respectively, all P > 0.05).

CONCLUSION

Artemisia pollen is the main pollen allergen in Beijing, EIT treatment was effective to pollinosis.

摘要

目的

分析蒿草花粉症的临床特征及治疗方法。

方法

分析北京同仁医院14426例患者的皮肤点刺试验结果及2007年至2011年北京气象站的花粉浓度，以确定蒿草花粉症患者的临床特征及其与花粉浓度的相关性。患者给予白三烯受体拮抗剂（孟鲁司特）治疗2周，随后给予糠酸莫米松鼻喷雾剂治疗4周（提前干预组：n = 21），或仅给予糠酸莫米松鼻喷雾剂治疗4周（发病后治疗组：n = 16）。比较两组的鼻部症状评分。采用SPSS 16.0软件进行数据分析。

结果

蒿草花粉症占所有皮肤点刺试验阳性变应性鼻炎患者的30.8%（4442/14426），大多数蒿草皮肤点刺试验阳性结果为强阳性（3793/4442，85.4%）；蒿草花粉症患者的发病年龄高峰在19至30岁，发病时间集中在8月至9月，与蒿草花粉浓度高峰期一致；花粉季节前2周使用白三烯受体拮抗剂的提前干预治疗与发病后治疗相比，显著改善了打喷嚏、流涕和鼻痒症状（t值分别为3.28、3.92、3.09，均P < 0.01）。但两组的鼻塞和咳嗽症状无显著差异（t值分别为0.85、1.52，均P > 0.05）。